Product information and disease descriptionProduct descriptionProduct information
Product comparison
21 evidence topics · 21 sources
Competing products named by the sponsor
Ficerafusp alfa plus pembrolizumab: population definition and phase 1b HPV-negative results
Pembrolizumab-based regimens in HPV-negative disease: outcomes cited by the ficerafusp alfa phase 1b report
Pembrolizumab monotherapy: approved first-line indication
Pembrolizumab monotherapy: KEYNOTE-048 survival and response in the CPS 1 or greater population at 4-year follow-up
“The median OS was 14.9 months (95% CI, 11.5 to 20.6) for pembrolizumab alone versus 10.8 months (95% CI, 8.8 to 12.8) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.61; 95% CI, 0.46 to 0.81; nominal one-sided P = .00034), 12.3 months (95% CI, 10.8 to 14.8) versus 10.4 months (95% CI, 9.0 to 11.7) in the CPS ≥ 1 population (HR, 0.74; 95% CI, 0.61 to 0.89; nominal one-sided P = .00080)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ORR was 23.3% (11 CR/20 PR) for pembrolizumab alone versus 36.1% (4 CR/40 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 19.1% (15 CR/34 PR) versus 34.9% (7 CR/82 PR) in the CPS ≥ 1 population, and 16.9% (15 CR/36 PR) versus 36.0% (8 CR/100 PR) in the total population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pembrolizumab plus platinum and fluorouracil: approved first-line indication
Pembrolizumab plus platinum and fluorouracil: KEYNOTE-048 survival and response at 4-year follow-up
“The median OS was 14.7 months (95% CI, 10.3 to 19.3) for pembrolizumab-chemotherapy versus 11.1 months (95% CI, 9.2 to 13.0) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.62; 95% CI, 0.46 to 0.84; nominal one-sided P = .00082), 13.6 months (95% CI, 10.7 to 15.5) versus 10.6 months (95% CI, 9.1 to 11.7) in the CPS ≥ 1 population (HR, 0.64; 95% CI, 0.53 to 0.78; nominal one-sided P = .00001), and 13.0 months (95% CI, 10.9 to 14.7) versus 10.7 months (95% CI, 9.3 to 11.7) in the total population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ORR was 43.7% (13 CR/42 PR) for pembrolizumab-chemotherapy versus 38.2% (4 CR/38 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 37.2% (17 CR/73 PR) versus 35.7% (7 CR/77 PR) in the CPS ≥ 1 population, and 36.3% (18 CR/84 PR) versus 36.3% (8 CR/93 PR) in the total population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
KEYNOTE-048 population: HPV status and PD-L1 distribution
“Eligible patients were age ≥ 18 years with previously untreated R/M squamous cell carcinoma of the oropharynx (known p16 expression), oral cavity, hypopharynx, or larynx, which was incurable by local therapy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Random assignment was stratified by PD-L1 expression (tumor proportion score ≥ 50% v < 50%), p16 expression for oropharyngeal cancer (positive v negative), and Eastern Cooperative Oncology Group performance status (0 v 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cetuximab plus platinum and fluorouracil (EXTREME): approved first-line indication and population
Cetuximab plus platinum and fluorouracil (EXTREME): efficacy results
| Outcome | Result |
|---|---|
| Median overall survival, cetuximab with platinum-based therapy and fluorouracil (n=222), months | “10.1” |
| Median overall survival, platinum-based therapy and fluorouracil (n=220), months | “7.4” |
| Overall survival hazard ratio (95% CI) | “0.80 (0.64, 0.98)” |
| Median progression-free survival, cetuximab arm, months | “5.5” |
| Median progression-free survival, control arm, months | “3.3” |
| Objective response rate, cetuximab arm | “35.6%” |
| Objective response rate, control arm | “19.5%” |
Petosemtamab plus pembrolizumab: LiGeR-HN1 phase 3 topline results
Petosemtamab plus pembrolizumab: LiGeR-HN1 eligibility and HPV classification
“p16 status is measured only in patients with oropharyngeal tumors; all other tumor locations are designated as p16 negative for the purposes of stratification.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Randomization will be stratified based on p16 status (positive vs. negative) and PD-L1 CPS (<20 vs. ≥20), as determined by central laboratory testing, and ECOG PS (0 vs. 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Petosemtamab plus pembrolizumab: phase 2 first-line cohort
Amivantamab plus pembrolizumab: OrigAMI-4 cohort 2, first-line, p16-positive oropharyngeal cancer excluded
“Cohort 2 of the phase 1b/2 OrigAMI-4 (NCT06385080) study enrolled participants with previously untreated R/M HNSCC and PD-L1 combined positive score ≥1.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with p16-positive oropharyngeal cancer and prior anti-EGFR or anti-PD-(L)1 therapy were excluded.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At a median follow-up of 13.6 months, confirmed ORR was 59% (95% CI, 42-74), with 7 (18%) complete responses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median PFS was 7.7 months (95% CI, 5.0-NR); median OS was NR.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Amivantamab plus pembrolizumab and carboplatin: OrigAMI-4 cohort 5, first-line
Amivantamab plus pembrolizumab and carboplatin: OrigAMI-5 phase 3 design and population
Amivantamab and hyaluronidase: accelerated approval in previously treated disease
| Outcome | RYBREVANT FASPRO (N=102) |
|---|---|
| Overall response rate (95% CI) | “42% (32%, 52%)” |
| Complete response | “15%” |
| Partial response | “28%” |
| Patients with duration of response of 6 months or longer | “56%” |
Enfortumab vedotin plus pembrolizumab: EV-202 first-line cohort
“Eligible patients had R/M HNSCC, programmed cell death ligand 1 (PD-L1) combined positive score (CPS) ≥1, and no prior systemic therapy in the R/M setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary analysis included 41 patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sixteen patients achieved a response, and cORR was 39% [95% confidence interval (CI), 24.2–55.5]. The complete response rate was 9.8%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median PFS was 5.1 months (95% CI, 3.5–not estimable).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with p16-positive oropharyngeal cancer ( n = 11), the cORR was 81.8%, in contrast to 23.3% in patients with non-HPV–associated disease ( n = 30).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“b For oropharyngeal squamous cell carcinoma only, patients without oropharyngeal cancer were considered HPV–negative.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients also did not undergo any testing to confirm their HPV status.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote